Filtered By:
Condition: Migraine
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
Reactivation of Herpes Zoster After Recombinant Vaccine (Shingrix): A Case Report
We describe a rare case of varicella infection reactivation after routine zoster vaccination in an immunocompetent female in her 60s who developed dermatomal pruritic and vesicular rash one week after receiving Shingrix vaccine, along with fever, sweating, headache, and fatigue. The patient was treated as a case of herpes zoster reactivation with a seven days course of acyclovir. She continued to do well on follow-up with no significant complications. Though uncommon, it is important for healthcare providers to recognize this adverse reaction to expedite testing and treatment.PMID:36874700 | PMC:PMC9979095 | DOI:10.7759/cureus.34431
Source: Herpes - March 6, 2023 Category: Infectious Diseases Authors: Feras Altukhaim May Mutlaq Mohammed Alghamdi Salha Hakami Source Type: research
Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System
CONCLUSION: In a national surveillance system, headache was a commonly reported post-vaccination adverse event; a small subset of reports was considered serious. The development of standardized vaccine-related case definitions could be useful for better evaluating headache as an adverse event during vaccine development, and may reduce vaccine hesitancy especially in headache-prone individuals.PMID:36651626 | DOI:10.1111/head.14458
Source: Headache - January 18, 2023 Category: Neurology Authors: Alexandra N Cocores Peter J Goadsby Teshamae S Monteith Source Type: research
Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting
Curr Pain Headache Rep. 2022 Nov 23. doi: 10.1007/s11916-022-01094-y. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: The aim of this review is to characterize headache as a vaccine adverse event (VAE) in clinical trials.RECENT FINDINGS: Of the recent phase III vaccine RCTs (non-COVID-19), 53 studies reported on headache (13 infectious agents). The median rate (interquartile range) of headache was 15.6% (IQR: 9.6-37.6%). Of these, 24.5% of the RCTs reported headache greater in the vaccine group compared to the placebo/control group. In the herpes zoster vaccination trials, headache was more common in all active groups: me...
Source: Herpes - November 23, 2022 Category: Infectious Diseases Authors: Kimberly N Garces Alexandra N Cocores Peter J Goadsby Teshamae S Monteith Source Type: research
Sequential Data-Mining for Adverse Events after Recombinant Herpes Zoster Vaccination Using the Tree-Based Scan Statistic
In this study, the binomial tree-based scan statistic was applied sequentially to detect adverse events in Days 1-28 compared with Days 29-56 after recombinant herpes zoster (RZV) vaccination, with 5 looks at the data and formal adjustment for the repeated analyses over time. IBM Marketscan data on commercially insured persons 50+ years of age receiving RZV during January 1, 2018-May 5, 2020 were used. With 999,876 doses of RZV included, statistically significant signals were detected only for unspecified adverse effects/complications following immunization, with attributable risks as low as 2 excess cases per 100,000 vacc...
Source: Am J Epidemiol - October 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research
Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
IDCases. 2022 Jul 13;29:e01563. doi: 10.1016/j.idcr.2022.e01563. eCollection 2022.ABSTRACTAs a result of the COVID-19 pandemic, mRNA vaccination has become widespread. Recently, it has been suggested that instances of herpes zoster increase following mRNA COVID-19 vaccination. Herein, we describe the first case of zoster sine herpete (ZSH) after mRNA vaccination for COVID-19. A 60-year-old Japanese immunocompetent man presented with fever, fatigue, headache, cervical pain, and lumbar pain, which developed after receiving a second dose of BNT162b2 mRNA COVID-19 vaccination. Whereas most symptoms improved with symptomatic tr...
Source: Herpes - July 20, 2022 Category: Infectious Diseases Authors: Ryutaro Tanizaki Yayoi Miyamatsu Source Type: research
